Gallium maltolate, tris(3-hydroxy-2-methyl-4H-pyran-4-onato)gallium (GaM), is 
INTRODUCTION
Gallium is a semi-metallic element that has shown therapeutic activity in metabolic bone disease, hypercalcemia and cancer [1] . It is approved for use in the United States as citrate-chelated gallium nitrate solution for intravenous infusion to treat hypercalcemia of malignancy [2] . Gallium reduces plasma calcium by inhibiting bone resorption, predominately through selective actions on osteoclasts and osteoblasts [1] . Clinical studies have shown that gallium administered intravenously or subcutaneously can reduce the abnormally high turnover of bone characteristic of Paget's disease [3] and can prevent osteolysis, ameliorate pain, and extend survival in patients with multiple myeloma [4, 5] . Gallium has also been suggested as a possible treatment for osteoporosis [2] due to its potent antiresorptive as well as possible bone-forming (anabolic) activities.
Numerous clinical studies have found gallium to have antineoplastic activity, particularly in some lymphomas [6] , urothelial carcinoma [7] , and nonsquamous cell cervical carcinoma [8] . As the antiproliferative properties of gallium extend to some micro-organisms, gallium has been suggested as a potential antibiotic, particularly for some intracellular infections such as tuberculosis [9] , and as an antiretroviral agent, particularly against human immunodeficiency virus [10] .
An orally active gallium compound was sought as a more convenient, comfortable, safe, and less costly alternative to parenterally administered gallium; in addition, such a compound could be used for chronic, widespread diseases such as postmenopausal osteoporosis. Gallium is absorbed very poorly when orally administered as salts such as the chloride or nitrate [11] [12] [13] , due in part to hydrolysis that produces low-solubility polymerized gallium oxide hydroxides in the gastrointestinal fluids. In the animal Chemistry and Pharmacokinetics of Gallium Maltolate, A Compound With High Oral Gallium Bioavailability and clinical studies reported here, gallium maltolate, tris(3-hydroxy-2-methyl-4H-pyran-4-onato)gallium (GaM), is found to provide oral gallium absorption at least several times higher than from gallium salts. This high oral bioavailability permits therapeutically useful blood gallium levels to be achieved without the need to orally administer large and possibly irritating or toxic doses of drug. In addition, the oral administration of gallium has been proposed to selectively increase gallium uptake by tumors and to reduce renal toxicity relative to parenteral administration [12] .
Gallium maltolate is a coordination complex of a trivalent gallium ion with three deprotonated maltol (maltolate) groups (Figure 1 ). Maltol (2-methyl-3-hydroxy-4H-pyran-4-one)is produced by some plants and is commonly formed when sugars are heated: it is largely responsible for the scent of cotton candy and contributes significantly to the fragrance of many cakes, cookies, and candies. Its ability to provide a "fresh-baked" fragrance and to enhance sweet flavors has led to its extensive use as a food additive [14] . Maltol loses its hydroxyl proton at neutral to basic pH levels, forming the maltolate anion; this anionic molecule forms a strong bidentate chelate with gallium, as well as with iron, zinc, aluminum, vanadium, and many other metals (e.g. [15] [16] [17] [18] [19] 15 .67 weight percent Ga, these doses contain, respectively, 15.7, 31.3, 47.0, and 78.4 mg of Ga. Each dosage was administered to three subjects; the subjects were between the ages of 27 and 51, and all the subjects were male except for one female in the 300 mg group and one in the 500 mg group. The health of each subject was closely monitored during the study through daily (for four days) measurements of vital signs, blood chemistry, CBC with differentials and platelets, fecal occult blood, creatinine, and BUN, plus urinalysis with microscopic evaluation; on the fourth day following dosing, these tests were supplemented with a physical examination and 12-lead electrocardiogram, and all of these tests were repeated at 14+3 days post-dosing.
MATERIALS AND METHODS
A 5 To compare with our clinical results on oral gallium maltolate, data on intravenously administered gallium were obtained from the study of Kelsen et al. [22] . Serum gallium concentrations were reported by these authors for three cancer patients who received rapid intravenous doses of citrate-chelated gallium nitrate. One patient experienced renal failure and another had been treated immediately prior to gallium administration with cisplatin, adriamycin, and cyclophosphamide. The remaining patient (with malignant melanoma) had normal renal function and was not reported to have been heavily treated with toxic compounds immediately before gallium administration, and so was chosen as an example in the present study. This patient received 700 mg/M 2 of gallium nitrate. Assuming a surface area of 1.75 M2, this dose is equivalent to approximately 1225 mg Ga(NO). As Ga(NO) contains 27.26 wt. percent Ga, a dose of 1225 mg contains approximately 334 mg Ga. The patient had a blood sample drawn prior to gallium administration, and other samples drawn at 0.083, 0.167, 0.25, 0.5, 1, 2, 4, 24, 48, and 104 hours following rapid intravenous administration of the gallium. The blood samples were centrifuged and the plasma analyzed for gallium concentration using flameless atomic absorption spectrometry.
To compare our clinical results with those for an orally administered gallium salt, pharmacokinetic data from a study by Collery et al. [12] were used. In their study a single oral dose of 800 mg GaCI (containing 317 mg Ga) was administered to eighteen cancer patients; blood samples were drawn at intervals up to 96 h following dosing, and serum Ga concentrations were determined by atomic absorption spectrometry. Out of plane. Wavenumber (cm" Figure 2 . Representative infrared absorption spectrum for gallium maltolate.
RESULTS
Molecular and crystal structure: The structure of the GaM molecule based on the single-crystal X-ray diffraction study is shown in Figure 3 , and the atomic and unit cell parameters of the crystal structure are presented in Tables 2 4. The structure is essentially the same as that for aluminum maltolate [16] . Refinement 
where M is the number of reflections and N is the number of parameters refined Dog bioavailability study
Results of the dog bioavailability study are summarized in Figure 4 and The data for oral GaM are plotted for each dose group in Figure 5 . Data for i.v. GaN and oral GaCIz are plotted in Figure 6 . Calculated curves based on two-compartment pharmacokinetic models are shown in both these figures. Cumulative urinary excretion for each dose group is shown in Figure 7 . Estimated (16) 58 (14) 69 (41) 77 (51) K21 half life (h)
53 (29) 53 (20) 58 (67) 63 (103) AUC0-o (lg h/mL) Table  6 ; estimated pharmacokinetic parameters for i.v. GaN based on two-and three-compartment models are presented in Table 7 . DISCUSSION Semilogarithmic plots of the clinical serum Ga data (Figures 5,6) show that single compartment, firstorder models (straight lines) are inadequate to model the oral GaM, oral GaCI, or i.v. GaN data, and that multi-compartment models are required. A two-compartment model provides a good fit to the oral GaM data, though the latest data point is generally underestimated (Figure 5 ). Although a threecompartment model will allow the latest data point to be better fit, use of such a model could not be justified without further information on gallium distribution and metabolism that support the existence and nature of the compartments, or without data points at later times that support the presence of a third elimination phase. AUC0-oo (lg h/mL) 365 (506) 710 (13003) Cmax (gg/mL)
Vss (L) 135 (87) Similarly, the i.v. GaN data may be better fit using a three-compartment than a two-compartment model, but the lack of data beyond only 104 h makes the use of a three-compartment model highly speculative and results in very high fitting errors (Table 7 ). There appears, however, to be some justification for adding a third elimination phase in this case, due to the very rapid initial Ga elimination (half life = hr) that is not observed for orally administered GaM (Table 6 ).
It is noted that when ionic gallium is administered rapidly into the bloodstream, much of it is not able to bind immediately to transferrin (the predominate carrier of serum Ga at equilibrium); instead, significant amounts of anionic gallate (Ga(OH),-) are formed [1, 24] . Gallate Figure 7 , Table 6 ). Inspection of the urinary excretion curves (Figure 7) shows that although Ga excretion clearly appears to continue past 72 h, the decreasing slopes of the curves suggest that the ultimate cumulative excretion values are unlikely to be more than two or three times the measured 2% value. In contrast, Kelsen et al. [22] The similarity of serum Ga data for the 300 mg and 500 mg groups ( [22] . The large difference is hypothesized to result from the formation of significant gallate [Ga(OH)4-] in blood plasma following the rapid i.v. administration of gallium nitrate. Gallate, as a smali, charged molecule, will be rapidly excreted by the kidneys. In contrast, gallium orally absorbed from GaM is expected to follow the typical pathway for orally absorbed iron into plasma, with nearly all ending up bound to transferrin. This protein-bound gallium is not expected to have high urinary excretion; it may be excreted into the feces via bile.
5. The apparent nearly complete binding of gallium to plasma transferrin following oral administration of GaM appears to greatly reduce the potential for renal toxicity when compared to i.v. Ga nitrate. In addition, antineoplastic efficacy is expected to be enhanced, as most cancer cells are highly avid for transferrin-bound Ga relative to other forms of Ga [36]. 6 . Gallium maltolate appears to be a promising pharmaceutical compound for the oral administration of gallium.
